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Abstract
A patient-derived nude-mouse model of soft-tissue sarcoma has been established and
treated in the following groups: (1) untreated controls; (2) gemcitabine (GEM) (80 mg/kg, ip,
weekly, 3 weeks); (3) Pazopanib (100 mg/kg, orally, daily, 3 weeks) and (4) Salmonella
typhimurium A1-R (5 × 107 CFU/body, ip, weekly, 3 weeks). The sarcoma was resistant to
GEM (p = 0.879). Pazopanib tended to reduce the tumor volume compared to the untreated
mice, but there was no significant difference (p = 0.115). S. typhimurium A1-R significantly
inhibited tumor growth compared to the untreated mice (p = 0.001). S. typhimurium A1-R
was the only effective treatment for the soft-tissue sarcoma nude mouse model among all
treatments including a newly approved multiple tyrosine kinase inhibitor; Pazopanib. These
results suggest tumor-targeting S. typhimurium A1-R is a promising treatment for chemo-
resistant soft-tissue sarcoma.
Introduction
Soft-tissue sarcomas are rare mesenchymal cancers comprising approximately 50 histological
types [1]. The yearly incidence of soft-tissue sarcomas in the USA is 11,280 cases, with 3,900
deaths. Patients with metastatic soft-tissue sarcomas have a median overall survival of about
12 months.
Pazopanib (Votrient) is a multiple tyrosine kinase inhibitor approved for the treatment of
advanced (unresectable and/or metastatic) soft-tissue sarcomas in patients who have received
prior chemotherapy. Pazopanib improved progression-free survival in a Phase III clinical trial [2].
An attenuated strain of Clostridium novyi (C. novyi-NT) was used to treat a human patient
who had an advanced leiomyosarcoma. Treatment was intratumor (i.t.) injection of C.
novyi-NT spores. C. novyi-NT regressed the tumor within and surrounding the bone [3].
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Our laboratory has previously developed a genetically-modified bacteria strain, Salmonella
typhimurium A1-R, selected for tumor-targeting in vivo. S. typhimurium A1-R is auxotrophic
for leu and arg [4]. The strain targets and grows in tumors. In contrast, normal tissue is cleared
of these bacteria even in immunodeficient athymic mice. S. typhimurium A1-R is effective
against prostate cancer [5], breast cancer [6, 7], pancreatic cancer [8–11], glioma [12, 13], lung
cancer [14], fibrosarcoma [15] and osteosarcoma [16].
In the present study, we report the efficacy of S. typhimurium A1-R against a human patient
chemo-resistant sarcoma growing in nude mice. Tumors growing in nude mice can faithfully
replicate important features of the patient’s cancer, such as tumor markers even after passage
[17, 18].
Materials and Methods
Animals
Male athymic nu/nu nude mice (AntiCancer Inc., San Diego, CA), 4–6 weeks old, were used in
this study. Mice were kept in a barrier facility under HEPA filtration. Mice were fed with auto-
claved laboratory rodent diet. All mouse surgical procedures and imaging were performed with
the animals anesthetized by intramuscular injection of 50% ketamine, 38% xylazine, and 12%
acepromazine maleate (0.02 ml solution). All animal studies were conducted with an AntiCan-
cer Institutional Animal Care and Use Committee (IACUC)-protocol specifically approved for
this study and in accordance with the principals and procedures outlined in the National Insti-
tute of Health Guide for the Care and Use of Animals under Assurance Number A3873-1.
Specimen collection
The patient provided informed written consent and samples were procured and the study was
conducted under the approval of the Institutional Review Board of the UC San Diego Medical
Center.
Establishment of patient nude mouse model of sarcoma
Tumor tissues were obtained from the patient with a metastatic soft-tissue sarcoma of the ret-
roperitoneum at biopsy and cut into fragments (3-mm3) and transplanted subcutaneously in
nude mice. Tumors in the present study were in their second passage.
Preparation of bacteria
S. typhimurium A1-R was grown overnight on LB medium and then diluted 1:10 in LB
medium. Bacteria were harvested at late-log phase, washed with PBS, and then diluted in PBS.
Bacteria were then used for experiments [6].
Treatment of soft-tissue sarcoma in nude mice
The patient sarcoma established in nude mice was passaged subcutaneously to 20 nude mice to
determine the efficacy of various treatments. Four weeks after implantation, the mice in each
model were randomized to 6 mice in the untreated control and 4 groups of 5 mice in each treat-
ment group and treated as follows: (1) untreated control; (2) gemcitabine (GEM, Eli Lilly and
Company, Indianapolis, IN, USA) (80 mg/kg, ip, weekly, 3 weeks); (3) Pazopanib (Selleck
Chemicals, Houston, TX, USA, 100 mg/kg, orally, daily, 3 weeks) and (4) S. typhimurium A1-R
(5 × 107 CFU/body, ip, weekly, 3 weeks). Tumor size was evaluated every 3 to 4 days by caliper
measurements. The approximate volume of the mass was calculated using the formula 4/3π•
(d/2)2• D/2, where d is the minor tumor axis and D is the major tumor axis. Body weight of the
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mice was measured on a balance once a week. Relative tumor volume and body weight were
calculated by comparison to Day 1. The endpoint of the experiment was when tumor size in
the untreated control mice became approximately 2 cm. The method of euthanasia was CO2
inhalation.
Tissue histology
Tumor samples were removed with surrounding normal tissues at the time of resection. Fresh
tissue samples were fixed in 10% formalin and embedded in paraffin before sectioning and
staining. Tissue sections (5 μm) were deparaffinized in xylene and rehydrated in an ethanol
series. Hematoxylin and eosin (H & E) staining was performed according to standard proto-
cols. The sections were examined using a BH-2 microscope (Olympus, Tokyo, Japan) equipped
with a INFINITY1 2.0 megapixel CMOS digital camera (Lumenera Corporation, Ottawa, Can-
ada). All images were acquired using INFINITY ANALYZE software (Lumenera Corporation)
without post-acquisition processing.
Evaluation of histopathological response to treatment
Histopathological response to treatment was defined according to Evans’s grading scheme:
Grade I, little (<10%) or no cancer cell destruction is evident; Grade IIa, destruction of 10%-
50% of cancer cells; Grade IIb, destruction of 51%-90% of cancer cells; Grade III, few (<10%)
viable-appearing cancer cells are present; Grade IV, no viable cancer cells are present [11, 19].
Confocal imaging of S. typhimurium A1-R-GFP in sarcoma tissue
Resected sarcoma specimens from mice treated with S. typhimurium A1-R were embedded
with optimal cutting temperature (OCT) compound (Tissue-Tek; Sakura Finetek Europe BV,
Zoeterwude, Netherlands) and preserved in liquid nitrogen. Frozen sections of 7–10 μm thick-
ness were prepared with a CM1850 cryostat (Leica, Wetzlar, Germany). The frozen sections
were directly observed with a confocal microscope (Fluoview FV1000, Olympus, Tokyo,
Japan). Excitation sources were semiconductor lasers at 473 nm for GFP excitation. After con-
focal imaging, frozen sections were fixed in 10% formalin and H & E staining was performed.
Culture of GFP-labeled S. typhimurium A1-R bacteria from tumors and
organs
Subcutaneous tumors and normal nude mouse organs (blood and liver) were removed at the
termination of the treatment experiments. Bacteria were isolated from the tumors and organs
and cultured in LB agar for 24 hours, and imaged with the OV100 small animal imaging system
(Olympus, Tokyo, Japan) [20].
Statistical analysis
PASW Statistics 18.0 (SPSS, Inc) was used for all statistical analyses. The Student’s t-test was
used to compare continuous variables between two groups. A p value of 0.05 was considered
statistically significant for all comparisons.
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Results and Discussion
Soft-tissue patient sarcoma grown in nude mice recapitulates the
histology of the original tumor
The majority of the original-tumor section was comprised of sarcomatous high grade spindle
cells of varying sizes, demonstrating abundant, finely granular cytoplasm and atypical, pleo-
morphic, round–to-elongated nuclei with irregular nuclear membranes, an open chromatin
pattern and prominent nucleoli (Fig 1A). The mouse-grown tumors had histological structures
similar to the original tumor (Fig 1B).
S. typhimurium A1-R is highly effective on the patient soft-tissue
sarcoma in nude mice
The relative tumor volume on day 22, compared to day 1, of each group was as follows: (1)
untreated control: 6.61 ± 2.37; (2) GEM: 6.39 ± 2.26; (3) Pazopanib: 3.94 ± 2.71; (4) S. typhi-
murium A1-R: 1.58 ± 0.37 (Fig 2). The sarcoma did not significantly respond to GEM
(p = 0.879). Pazopanib tended to reduce the tumor volume compared to the untreated mice,
but there was not a significant difference (p = 0.115). S. typhimurium A1-R significantly inhib-
ited the sarcoma tumor growth compared to the untreated control mice (Fig 2) (p = 0.001).
Sizes of all tumors are listed in the S1 Table. No body weight loss was found in any treatment
groups.
Histological response to treatment
Histopathological response to each treatment was defined according to Evans’s grading
scheme. In the control (no treatment) and GEM-treated sections, the tissue sections from the
tumor were occupied by viable cancer cells (Fig 3A and 3B). Approximately 40% of cancer cells
were destroyed and replaced by stromal cells in the tumor sections treated with Pazopanib (Fig
3E). Tumors treated with S. typhimurium A1-R consisted of 2 components; one was a viable-
like component and the other one was a necrotic component. The viable-like component was
occupied by cancer cells (Fig 3D). In contrast, no viable cancer cell were detected in a necrotic
component of the S. typhimurium A1-R-treated tumor (Fig 3E). Although the viable cancer
Fig 1. Tumor histology. A)Histology of the original patient sarcoma.B)Histology of the mouse grown sarcoma.
doi:10.1371/journal.pone.0134324.g001
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cells were found, they did not form a tumor as can be seen from Fig 2. The untreated control
and GEM were judged as grade I; Pazopanib as IIa; S. typhimurium A1-R of a viable-like com-
ponent as grade I and the necrotic component as IV. The necrotic component was not detected
in any treatment group except for S. typhimurium A1-R (Fig 3A–3E). Tumor heterogeneity
may be a factor in the observed chemoresistance of the soft tissue sarcoma that was overcome
by S. typhimurium A1-R.
GFP-labeled S. typhimurium A1-R was isolated from the tumor (Fig 4), but not from blood
and only minimally from liver, indicating the tumor was effectively targeted by S. typhimurium
A1-R.
S. typhimurium A1-R was the only effective treatment for the soft-tissue patient sarcoma
growing in nude mice including GEM and a newly approved multiple tyrosine kinase inhibitor;
Pazopanib. One factor in chemoresistance of solid tumors is that the majority of the cancer
cells within the tumor are in a chemoresistant G0/G1 quiescent cell-cycle phase [21]. We
have recently shown that quiescent cancer cells are sensitive to S. typhimurium A1-R [22].
S. typhimurium A1-R, unlike C. novyi-NT, is a facultative anaerobe and can be administered
systemically such as in the present study (i.p.), whereas C. novyi-NT seems to require i.t.
administration which makes it different to target metastasis. The results of the present study
indicate tumor-targeting S. typhimurium A1-R is a promising treatment for soft-tissue sarco-
mas. In future experiments, S. typhimurium A1-R will be tested in a series of patient soft tissue
sarcoma grown in mice as a bridge to the clinic, where we also intend to focus on sarcoma.
Fig 2. Drug-response of soft tissue sarcoma in nudemice. A representative image of nude mouse with the subcutaneous sarcoma in (A) the untreated
mice; (B)GEM-treated; (C) Pazopanib-treated or (D) Salmonella typhimurium A1-R-treated. Scale bars: 10 mm. (E)Growth curves of the subcutaneous
sarcoma’s treated with various drugs as described above. The values are mean relative tumor volume ± S.D. (bars) of five different tumors. ** p < 0.01,
compared to no treatment group. (F-G) Representative cross-sections of excised subcutaneous tumors from the control and treatment groups with type of
treatment indicated.
doi:10.1371/journal.pone.0134324.g002
Fig 3. Effect of treatment on histology in nudemice.Histopathological responses to treatments were defined according to Evans’s grading scheme. (A)
Treatment effect of control / no treatment was judged as grade I; (B)GEM treatment as grade I; (C) Pazopanib treatment as grade IIa; (D) S. typhimurium
A1-R of a viable-like area as grade I and (E) S. typhimurium A1-R of a necrotic area as grade IV. Scale bars: 200 μm.
doi:10.1371/journal.pone.0134324.g003
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Evaluation of biomarker expansion under various treatment regimens will be evaluated in
future experiments.
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Fig 4. Tumor-targeting of S. typhimuriumA1-R. Distribution of GFP-labeled S. typhimurium A1-R in tumors and organs. Representative images of GFP-
labeled S. typhimurium A1-R bacteria culture isolated from the tumor and the normal organs (blood and liver) of the mice treated with S. typhimurium A1-R.
GFP-labeled S. typhimurium A1-R were clearly detected only in the tumor. Only a few GFP-labeled S. typhimurium A1-R were detected in the liver and no
GFP-labeled S. typhimurium A1-R was detected in blood. Scale bars: 10 mm.
doi:10.1371/journal.pone.0134324.g004
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